StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) KPIs and segments

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$272.70−6.00 (-2.15%)

Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Johnson & Johnson · năm tài chính kết thúc 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q3 2026 ended September 27, 2026)

Nhìn nhanh KPI của Johnson & Johnson: 51 chỉ số vận hành, trong đó có Consolidated sales to customers, Innovative Medicine Segment Total và Neuroscience Therapeutic Area Total, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Innovative Medicine($M)2
16,75716,38415,42615,76315,56315,20213,87314,33214,58014,49013,56213,722
U.S.($M)
10,4479,9798,8719,6899,4029,1618,0928,9778,8718,5107,6128,079
International($M)
6,3106,4056,5556,0746,1616,0415,7815,3555,7095,9805,9505,643
MEDTECH($M)2
8,6428,9268,6368,8018,4308,5418,0208,1887,8917,9577,8217,673
U.S.($M)
4,5124,5544,4594,5064,3064,3834,2134,2274,0384,0594,0083,930
International($M)
4,1304,3724,1774,2954,1244,1583,8073,9613,8533,8983,8133,743
U.S.($M)
14,95914,53313,33014,19513,70813,54412,30513,20412,90912,56911,62012,009
International($M)
10,44010,77710,73210,36910,28510,1999,5889,3169,5629,8789,7639,386
Europe($M)
5,4055,7265,8485,5985,4405,3875,1104,9214,9145,2145,1634,962
Asia-Pacific, Africa($M)
3,6503,7423,5913,5003,6143,6063,3113,2603,4753,4523,4063,258
Western Hemisphere, excluding U.S.($M)
1,3851,3091,2931,2711,2311,2061,1671,1351,1731,2121,1941,166
Innovative Medicine($M)
12,27112,08811,03611,78711,89111,2249,85310,81811,03110,88710,192
MEDTECH($M)
5,0455,1894,9354,8284,8184,9034,6944,5924,5104,7094,701
Innovative Medicine($M)
5,0666,2495,3175,0586,4465,5525,2104,0094,4825,4594,969
MEDTECH($M)
7761,1771,2392011,2871,2041,421721,0591,0891,520
MEDTECH($M)
-599-593-509-827-603-591-480-814-555-581-493
Innovative Medicine($M)
-704-653-508-910-479-411-276-739-418-321-232
MEDTECH($M)
86,21486,58186,17986,48286,50286,74585,11184,32274,710
Innovative Medicine($M)
78,94478,85678,11878,05774,42275,48758,72757,07058,324
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Consolidated sales to customers ($M)($M)3
25,39925,31024,06224,56423,99323,74321,89322,52022,47122,44721,38321,395
Geographic sales — United States ($M)($M)1
14,95914,53313,33014,19513,70813,54412,30513,20412,90912,56911,62012,009
U.S. reported & operational sales growth YoY (%)(%)
9.1%7.3%8.3%7.5%6.2%7.8%5.9%10.0%7.6%7.8%7.8%11.0%
Geographic sales — International ($M)($M)6
10,44010,77710,73210,36910,28510,1999,5889,3169,5629,8789,7639,386
Europe sales ($M)($M)3
5,4055,7265,8485,5985,4405,3875,1104,9214,9145,2145,1634,962
Europe reported sales growth YoY (%)(%)
-0.6%6.3%14.5%13.8%10.7%3.3%-1.0%-0.8%4.0%1.6%-7.6%-3.2%
Europe operational (constant-currency) sales growth YoY (%)(%)
1.0%3.3%2.7%5.2%4.4%-1.9%2.2%-0.2%3.0%3.4%-7.7%-5.8%
Europe currency (FX) impact YoY (%)(%)
-1.6%3.0%11.8%8.6%6.3%5.2%-3.2%-0.6%1.0%-1.8%0.1%2.6%
Western Hemisphere excluding U.S. sales ($M)($M)3
1,3851,3091,2931,2711,2311,2061,1671,1351,1731,2121,1941,166
Western Hemisphere ex-U.S. reported sales growth YoY (%)(%)
12.5%8.5%10.8%12.0%4.9%-0.5%-2.3%-2.7%0.3%6.7%11.0%14.0%
Western Hemisphere ex-U.S. operational sales growth YoY (%)(%)
8.0%2.7%2.5%11.0%7.3%6.2%9.2%17.6%20.3%22.6%21.3%18.1%
Western Hemisphere ex-U.S. currency (FX) impact YoY (%)(%)
4.5%5.8%8.3%1.0%-2.4%-6.7%-11.5%-20.3%-20.0%-15.9%-10.3%-4.1%
Asia-Pacific, Africa sales ($M)($M)3
3,6503,7423,5913,5003,6143,6063,3113,2603,4753,4523,4063,258
Asia-Pacific, Africa reported sales growth YoY (%)(%)
1.0%3.8%8.5%7.4%4.0%4.4%-2.8%0.1%0.5%-4.0%-1.1%9.7%
Asia-Pacific, Africa operational sales growth YoY (%)(%)
1.0%3.9%6.1%7.2%3.4%2.4%-0.6%0.9%1.5%1.9%5.0%12.1%
Asia-Pacific, Africa currency (FX) impact YoY (%)(%)
0.0%-0.1%2.4%0.2%0.6%2.0%-2.2%-0.8%-1.0%-5.9%-6.1%-2.4%
International reported sales growth YoY (%)(%)
1.5%5.7%11.9%11.3%7.6%3.2%-1.8%-0.7%2.2%0.2%-3.4%2.9%
International operational (constant-currency) sales growth YoY (%)(%)
1.8%3.4%3.9%6.6%4.4%0.6%2.1%2.5%4.6%5.1%-0.3%2.7%
International currency (FX) impact YoY (%)(%)
-0.3%2.3%8.0%4.7%3.2%2.6%-3.9%-3.2%-2.4%-4.9%-3.1%0.2%
Worldwide reported sales growth YoY (%)(%)3
5.9%6.6%9.9%9.1%6.8%5.8%2.4%5.3%5.2%4.3%2.3%7.3%
Worldwide operational (constant-currency) sales growth YoY (%)(%)
6.0%5.6%6.4%7.1%5.4%4.6%4.2%6.7%6.3%6.6%3.9%7.2%
Worldwide currency (FX) impact YoY (%)(%)
-0.1%1.0%3.5%2.0%1.4%1.2%-1.8%-1.4%-1.1%-2.3%-1.6%0.1%
Worldwide adjusted operational sales growth ex-A&D YoY (%)(%)
6.1%5.7%5.3%6.1%4.4%3.0%3.3%5.7%5.4%6.5%4.0%5.7%
Innovative Medicine Segment Total — Worldwide sales ($M)($M)7
16,75716,38415,42615,76315,56315,20213,87314,33214,58014,49013,56213,722
Innovative Medicine Segment Total — U.S. sales ($M)($M)1
10,4479,9798,8719,6899,4029,1618,0928,9778,8718,5107,6128,079
Innovative Medicine Segment Total — U.S. operational growth YoY (%)(%)
11.1%8.9%9.6%7.9%6.0%7.6%6.3%11.1%7.5%8.9%8.4%9.5%
Innovative Medicine Segment Total — International sales ($M)($M)1
6,3106,4056,5556,0746,1616,0415,7815,3555,7095,9805,9505,643
Innovative Medicine Segment Total — International operational growth YoY (%)(%)
3.0%3.6%4.3%7.9%4.3%-1.6%1.5%-1.0%4.4%6.4%-4.0%-3.1%
Innovative Medicine Segment Total — Worldwide reported growth YoY (%)(%)
7.7%7.8%11.2%10.0%6.8%4.9%2.3%4.4%4.9%5.5%1.1%4.2%
Innovative Medicine Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
7.9%6.8%7.4%7.9%5.3%3.8%4.2%6.1%6.3%7.8%2.5%4.0%
Innovative Medicine Segment Total — Worldwide currency (FX) impact YoY (%)(%)
-0.2%1.0%3.8%2.1%1.5%1.1%-1.9%-1.7%-1.4%-2.3%-1.4%0.2%
Innovative Medicine — Worldwide adjusted operational growth ex-A&D YoY (%)(%)
8.0%6.9%5.6%6.2%3.7%2.4%4.4%6.3%6.4%8.0%2.5%4.0%
Oncology Therapeutic Area Total — Worldwide sales ($M)($M)13
7,6027,4066,9736,8616,5296,3125,6785,4975,3805,0904,8144,618
Oncology Therapeutic Area Total — U.S. sales ($M)($M)1
4,2674,0693,6153,7933,4683,3853,0133,0192,8162,6362,3832,285
Oncology Therapeutic Area Total — U.S. operational growth YoY (%)(%)
23.0%20.3%20.0%25.6%23.2%28.4%26.4%32.2%26.9%27.4%26.2%23.0%
Oncology Therapeutic Area Total — International sales ($M)($M)1
3,3353,3373,3583,0693,0602,9282,6642,4762,5652,4552,4302,334
Oncology Therapeutic Area Total — International operational growth YoY (%)(%)
9.5%11.2%15.3%17.3%14.8%15.7%14.4%10.6%14.3%10.8%12.6%12.0%
Oncology Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
16.4%17.3%22.8%24.8%21.3%24.0%17.9%19.0%18.7%15.7%17.1%17.6%
Oncology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
16.7%16.1%17.8%21.9%19.2%22.3%20.4%21.3%20.5%18.6%18.8%17.2%
Oncology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.3%1.2%5.0%2.9%2.1%1.7%-2.5%-2.3%-1.8%-2.9%-1.7%0.4%
DARZALEX (daratumumab) — Worldwide sales ($M)($M)4
4,2394,2073,9643,9033,6723,5393,2373,0843,0162,8782,6922,550
DARZALEX (daratumumab) — U.S. sales ($M)($M)1
2,5282,4352,2082,3322,0882,0171,8291,7991,6841,6411,4641,395
DARZALEX (daratumumab) — U.S. operational growth YoY (%)(%)
21.1%20.7%20.7%29.6%24.0%23.0%24.9%28.9%23.0%24.2%22.9%22.5%
DARZALEX (daratumumab) — International sales ($M)($M)1
1,7111,7721,7561,5711,5841,5211,4091,2851,3321,2371,2281,155
DARZALEX (daratumumab) — International operational growth YoY (%)(%)
8.5%13.5%14.0%16.2%14.7%19.6%19.8%17.0%22.8%17.9%19.0%21.8%
DARZALEX (daratumumab) — Worldwide reported growth YoY (%)(%)
15.4%18.9%22.5%26.6%21.7%23.0%20.3%20.9%20.7%18.4%18.9%22.4%
DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
15.6%17.6%17.8%24.1%19.9%21.5%22.5%23.5%22.9%21.3%21.0%22.2%
DARZALEX (daratumumab) — Worldwide currency (FX) impact YoY (%)(%)
-0.2%1.3%4.7%2.5%1.8%1.5%-2.2%-2.6%-2.2%-2.9%-2.1%0.2%
ERLEADA (apalutamide) — Worldwide sales ($M)($M)4
1,023995949959936908771784790736689647
ERLEADA (apalutamide) — U.S. sales ($M)($M)1
423396342405378378292342337318285287
ERLEADA (apalutamide) — U.S. operational growth YoY (%)(%)
11.8%4.7%17.3%18.6%12.3%18.6%2.5%19.0%17.1%32.2%14.1%4.4%
ERLEADA (apalutamide) — International sales ($M)($M)1
600599607554558530479442453418404361
ERLEADA (apalutamide) — International operational growth YoY (%)(%)
7.7%9.7%15.5%17.5%17.6%22.8%23.1%25.7%34.0%32.8%40.6%34.0%
ERLEADA (apalutamide) — Worldwide reported growth YoY (%)(%)
9.4%9.5%23.1%22.4%18.4%23.4%11.9%20.9%25.4%29.8%27.0%19.8%
ERLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%)(%)1
9.4%7.6%16.2%18.0%15.3%21.0%14.6%22.7%26.3%32.5%28.4%19.0%
ERLEADA (apalutamide) — Worldwide currency (FX) impact YoY (%)(%)
0.0%1.9%6.9%4.4%3.1%2.4%-2.7%-1.8%-0.9%-2.7%-1.4%0.8%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide sales ($M)($M)4
710657597555524439369334286186157159
CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M)($M)1
472472433420396358318304258167140145
CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%)(%)
19.4%31.7%36.2%38.2%53.3%84.9%46.5%99.8%
CARVYKTI (ciltacabtagene autoleucel) — International sales ($M)($M)
23818516413512881513127201613
CARVYKTI (ciltacabtagene autoleucel) — Worldwide reported growth YoY (%)(%)
35.5%49.4%62.1%65.8%83.5%87.7%59.8%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide operational (constant-currency) growth YoY (%)(%)1
35.2%47.7%57.4%63.2%81.4%87.6%59.9%
CARVYKTI (ciltacabtagene autoleucel) — Worldwide currency (FX) impact YoY (%)(%)
0.3%1.7%4.7%2.6%2.1%0.1%-0.1%
IMBRUVICA (ibrutinib) — Worldwide sales ($M)($M)4
563599660684695735709731753770784788
IMBRUVICA (ibrutinib) — U.S. sales ($M)($M)1
145149143207211239235250259246265255
IMBRUVICA (ibrutinib) — U.S. operational growth YoY (%)(%)
-31.6%-37.6%-39.1%-17.4%-18.3%-2.7%-11.5%-2.0%-1.9%-6.4%-1.5%-19.8%
IMBRUVICA (ibrutinib) — International sales ($M)($M)1
420449517478483496474481494525518533
IMBRUVICA (ibrutinib) — International operational growth YoY (%)(%)
-12.6%-11.8%-1.4%-7.5%-6.6%-8.4%-4.2%-6.8%-7.2%-5.6%-5.6%-3.8%
IMBRUVICA (ibrutinib) — Worldwide reported growth YoY (%)(%)
-18.8%-18.6%-6.9%-6.5%-7.8%-4.5%-9.5%-7.2%-6.8%-8.5%-5.2%-8.9%
IMBRUVICA (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-18.4%-20.2%-13.9%-10.9%-10.6%-6.6%-6.7%-5.2%-5.5%-5.9%-4.3%-9.7%
IMBRUVICA (ibrutinib) — Worldwide currency (FX) impact YoY (%)(%)
-0.4%1.6%7.0%4.4%2.8%2.1%-2.8%-2.0%-1.3%-2.6%-0.9%0.8%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M)($M)4
320289257216198179141122896947
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. sales ($M)($M)1
201190175146136139113101685236
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%)(%)
47.9%36.8%55.1%45.6%99.7%68.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M)($M)
11999827061412821211711
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide reported growth YoY (%)(%)
62.3%60.8%82.7%78.0%69.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1
63.5%61.6%80.5%76.5%89.0%
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide currency (FX) impact YoY (%)(%)
-1.2%-0.8%2.2%1.5%122.0%
TECVAYLI (teclistamab) — Worldwide sales ($M)($M)4
312260202176177166151146135135133126
TECVAYLI (teclistamab) — U.S. sales ($M)($M)
236186127110115114105108105104101102
TECVAYLI (teclistamab) — International sales ($M)($M)1
777474666252463830303324
TECVAYLI (teclistamab) — International operational growth YoY (%)(%)
25.9%39.2%52.1%65.1%72.0%45.9%71.6%59.4%19.0%
TECVAYLI (teclistamab) — Worldwide reported growth YoY (%)(%)
76.6%56.5%33.5%20.8%31.3%23.1%13.3%15.8%20.6%42.9%94.0%
TECVAYLI (teclistamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
77.3%56.1%30.1%18.9%29.9%22.4%15.0%18.0%21.4%43.5%112.0%
TECVAYLI (teclistamab) — Worldwide currency (FX) impact YoY (%)(%)
-0.7%0.4%3.4%1.9%1.4%0.7%-1.7%-2.2%-0.8%-0.6%126.0%
TALVEY (talquetamab) — Worldwide sales ($M)($M)4
1711741521491221068685756958
TALVEY (talquetamab) — U.S. sales ($M)($M)1
11211210110585826868645950
TALVEY (talquetamab) — U.S. operational growth YoY (%)(%)
31.6%36.2%48.5%53.8%34.2%38.0%35.2%
TALVEY (talquetamab) — International sales ($M)($M)
59625144372418171298
TALVEY (talquetamab) — Worldwide reported growth YoY (%)(%)
40.9%63.3%76.7%75.8%60.8%55.0%48.4%
TALVEY (talquetamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
42.1%62.6%72.8%73.1%59.1%54.3%50.2%
TALVEY (talquetamab) — Worldwide currency (FX) impact YoY (%)(%)
-1.2%0.7%3.9%2.7%1.7%0.7%-1.8%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide sales ($M)($M)4
119113145125135150165181201
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. sales ($M)($M)1
5567951199
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. operational growth YoY (%)(%)
-41.4%-25.0%-38.9%-24.3%-7.3%-66.0%21.6%-41.3%-52.0%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International sales ($M)($M)1
115108139118127144154172191
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International operational growth YoY (%)(%)
-11.1%-26.8%-13.3%-28.5%-30.7%-24.4%-23.6%-20.7%-23.2%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%)(%)
-11.9%-25.1%-11.6%-30.9%-32.4%-30.0%-27.7%-25.9%-25.6%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1
-13.0%-26.8%-14.9%-28.3%-29.6%-27.5%-21.9%-22.1%-25.3%
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide currency (FX) impact YoY (%)(%)
1.1%1.7%3.3%-2.6%-2.8%-2.5%-5.8%-3.8%-0.3%
Other Oncology medicines — Worldwide sales ($M)($M)4
262226192-28320723821475868373-8
Other Oncology medicines — U.S. sales ($M)($M)
149131854361565439363733-32
Other Oncology medicines — International sales ($M)($M)1
11197106-3261471811603650454124
Other Oncology medicines — International operational growth YoY (%)(%)
-23.9%-45.7%-36.3%3.0%-25.6%-12.3%10.1%30.6%27.6%-6.0%-5.6%28.4%
Other Oncology medicines — Worldwide reported growth YoY (%)(%)
26.3%-4.6%-10.6%32.9%9.7%11.7%21.7%90.4%84.2%80.2%
Other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1
26.7%-3.9%-12.5%30.3%7.7%9.7%24.7%92.4%87.2%80.5%
Other Oncology medicines — Worldwide currency (FX) impact YoY (%)(%)
-0.4%-0.7%1.9%2.6%2.0%2.0%-3.0%-2.0%-3.0%-0.3%
Immunology Therapeutic Area Total — Worldwide sales ($M)($M)9
4,2213,8443,3803,8604,1683,9933,7074,2384,6214,7224,2474,595
Immunology Therapeutic Area Total — U.S. sales ($M)($M)1
2,8042,3721,8552,4952,6762,5052,1962,8563,0682,9782,4533,033
Immunology Therapeutic Area Total — U.S. operational growth YoY (%)(%)
4.8%-5.3%-15.5%-12.6%-12.8%-15.9%-10.5%-5.9%-3.9%4.0%0.2%8.1%
Immunology Therapeutic Area Total — International sales ($M)($M)1
1,4171,4731,5241,3641,4931,4891,5101,3831,5521,7441,7941,562
Immunology Therapeutic Area Total — International operational growth YoY (%)(%)
-4.8%-3.5%-6.4%-5.5%-6.3%-16.2%-11.5%-6.5%-2.1%13.2%11.0%17.7%
Immunology Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
1.3%-3.7%-8.8%-8.9%-9.8%-15.4%-12.7%-7.8%-4.7%5.0%3.3%11.6%
Immunology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
1.4%-4.6%-11.8%-10.3%-10.6%-16.0%-10.9%-6.1%-3.3%7.3%4.6%11.2%
Immunology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.1%0.9%3.0%1.4%0.8%0.6%-1.8%-1.7%-1.4%-2.3%-1.3%0.4%
TREMFYA (guselkumab) — Worldwide sales ($M)($M)4
2,3962,0461,6081,5891,4241,1869569491,007906808910
TREMFYA (guselkumab) — U.S. sales ($M)($M)1
1,7721,4651,0421,145989796599654691589509657
TREMFYA (guselkumab) — U.S. operational growth YoY (%)(%)
79.1%84.2%73.9%75.1%43.1%35.2%17.6%-0.6%9.1%30.8%25.4%21.6%
TREMFYA (guselkumab) — International sales ($M)($M)1
624581566445434391356295316317299252
TREMFYA (guselkumab) — International operational growth YoY (%)(%)
43.4%44.2%46.8%44.0%33.4%20.5%24.4%21.7%26.9%30.5%31.5%17.8%
TREMFYA (guselkumab) — Worldwide reported growth YoY (%)(%)
68.3%72.5%68.3%67.6%41.3%31.0%18.2%4.2%13.0%28.3%26.3%21.0%
TREMFYA (guselkumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
68.2%71.0%63.8%65.4%40.1%30.1%20.1%5.6%14.3%30.7%27.6%20.5%
TREMFYA (guselkumab) — Worldwide currency (FX) impact YoY (%)(%)
0.1%1.5%4.5%2.2%1.2%0.9%-1.9%-1.4%-1.3%-2.4%-1.3%0.5%
STELARA (ustekinumab) — Worldwide sales ($M)($M)4
7167406561,2301,5701,6531,6252,3492,6762,8852,4512,753
STELARA (ustekinumab) — U.S. sales ($M)($M)1
3683362207661,0221,0789811,6991,7701,8551,3961,786
STELARA (ustekinumab) — U.S. operational growth YoY (%)(%)
-64.0%-68.8%-77.6%-54.9%-42.3%-41.9%-29.8%-4.9%-7.5%2.1%-3.8%10.1%
STELARA (ustekinumab) — International sales ($M)($M)1
3494044354625495756446509061,0301,055967
STELARA (ustekinumab) — International operational growth YoY (%)(%)
-35.5%-31.1%-37.7%-32.3%-41.4%-45.6%-35.8%-29.6%-2.3%10.1%8.2%23.9%
STELARA (ustekinumab) — Worldwide reported growth YoY (%)(%)
-54.4%-55.2%-59.7%-47.7%-41.3%-42.7%-33.7%-14.7%-6.6%3.1%0.3%15.3%
STELARA (ustekinumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-54.0%-55.7%-61.7%-48.6%-42.0%-43.2%-32.3%-13.6%-5.7%4.9%1.1%14.5%
STELARA (ustekinumab) — Worldwide currency (FX) impact YoY (%)(%)
-0.4%0.5%2.0%0.9%0.7%0.5%-1.4%-1.1%-0.9%-1.8%-0.8%0.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide sales ($M)($M)4
568618647632687690659583516537554502
SIMPONI / SIMPONI ARIA (golimumab) — U.S. sales ($M)($M)1
269260269287309305292262299267254258
SIMPONI / SIMPONI ARIA (golimumab) — U.S. operational growth YoY (%)(%)
-13.2%-14.6%-7.8%9.6%3.6%14.0%14.8%1.3%-3.7%-6.3%-6.2%-7.8%
SIMPONI / SIMPONI ARIA (golimumab) — International sales ($M)($M)1
299358378345377387366321218270299244
SIMPONI / SIMPONI ARIA (golimumab) — International operational growth YoY (%)(%)
-20.3%-9.5%-4.1%3.7%69.8%40.8%29.7%44.2%-23.3%22.8%20.0%11.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide reported growth YoY (%)(%)
-17.3%-10.5%-1.7%8.4%32.9%28.6%18.9%16.2%-18.0%1.6%3.0%0.1%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-17.1%-11.7%-5.7%6.4%31.5%27.5%22.9%22.1%-13.6%7.1%6.8%0.8%
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide currency (FX) impact YoY (%)(%)
-0.2%1.2%4.0%2.0%1.4%1.1%-4.0%-5.9%-4.4%-5.5%-3.8%-0.7%
REMICADE (infliximab) — Worldwide sales ($M)($M)5
394338422370476455467359419393434429
REMICADE (infliximab) — U.S. sales ($M)($M)1
258215269248326283314231281231266294
REMICADE (infliximab) — U.S. operational growth YoY (%)(%)
-20.8%-24.1%-14.4%7.1%16.2%22.5%18.1%-21.4%-5.4%-16.7%-3.9%-7.4%
REMICADE (infliximab) — U.S. Exports ($M)($M)1
12101811193410927352735
REMICADE (infliximab) — U.S. Exports growth YoY (%)(%)
-37.1%-71.0%78.6%17.1%-30.9%-2.6%-64.2%-73.3%-28.9%7.9%-32.7%-15.1%
REMICADE (infliximab) — International sales ($M)($M)1
124112136110132138143117112127141100
REMICADE (infliximab) — International operational growth YoY (%)(%)
-7.5%-20.5%-10.5%-7.3%16.7%8.8%6.8%22.9%-6.5%-12.0%-14.2%-12.4%
REMICADE (infliximab) — Worldwide reported growth YoY (%)(%)
-17.3%-25.8%-9.5%3.2%13.6%15.9%7.5%-16.5%-9.1%-14.9%-10.9%-9.6%
REMICADE (infliximab) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-17.6%-26.4%-11.2%2.6%13.3%15.9%9.3%-15.0%-7.7%-13.4%-9.9%-9.4%
REMICADE (infliximab) — Worldwide currency (FX) impact YoY (%)(%)
0.3%0.6%1.7%0.6%0.3%0.0%-1.8%-1.5%-1.4%-1.5%-1.0%-0.2%
Other Immunology medicines — Worldwide sales ($M)($M)2
1471044640128101202
Other Immunology medicines — U.S. sales ($M)($M)
126853838128101202
Other Immunology medicines — International sales ($M)($M)
21189200000000
Neuroscience Therapeutic Area Total — Worldwide sales ($M)($M)9
2,3752,3372,1752,1152,0242,0511,6471,7751,7551,7821,8031,801
Neuroscience Therapeutic Area Total — U.S. sales ($M)($M)1
1,7331,6591,4941,4391,3671,3779681,1481,0941,1021,0541,022
Neuroscience Therapeutic Area Total — U.S. operational growth YoY (%)(%)
26.8%20.5%54.3%25.4%25.0%24.9%-8.1%12.3%5.6%7.1%
Neuroscience Therapeutic Area Total — International sales ($M)($M)1
642678681675658674679628662679749780
Neuroscience Therapeutic Area Total — International operational growth YoY (%)(%)
-1.7%-1.1%-6.3%4.3%-2.6%-2.6%-5.5%-16.8%-3.9%-6.0%-4.4%-2.0%
Neuroscience Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
17.3%14.0%32.0%19.1%15.3%15.1%-8.6%-1.5%0.8%-0.6%0.0%3.7%
Neuroscience Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
17.6%13.4%29.3%17.9%14.6%14.4%-7.0%-0.3%1.7%1.5%2.2%5.4%
Neuroscience Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.3%0.6%2.7%1.2%0.7%0.7%-1.6%-1.2%-0.9%-2.1%-2.2%-1.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M)($M)4
9981,0151,0389869299929031,0631,0491,0541,0561,011
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. sales ($M)($M)1
739738758704664732625796780784765733
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. operational growth YoY (%)(%)
11.4%0.8%21.2%-11.5%-14.9%-6.7%-18.2%8.6%6.8%8.8%7.2%8.0%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International sales ($M)($M)1
258278280281267260277267269269292278
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International operational growth YoY (%)(%)
-2.4%5.1%-4.9%1.9%-3.0%-5.1%-1.1%-1.8%-8.3%-9.0%-8.7%-15.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide reported growth YoY (%)(%)
7.3%2.3%15.0%-7.3%-11.3%-5.9%-14.5%5.1%1.9%2.2%1.2%0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide operational (constant-currency) growth YoY (%)(%)1
7.5%1.9%13.2%-8.2%-11.9%-6.3%-13.5%5.7%2.4%3.5%2.2%0.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide currency (FX) impact YoY (%)(%)
-0.2%0.4%1.8%0.9%0.6%0.4%-1.0%-0.6%-0.5%-1.3%-1.0%0.0%
SPRAVATO (esketamine) — Worldwide sales ($M)($M)4
624584468503459414320297284271225206
SPRAVATO (esketamine) — U.S. sales ($M)($M)1
559514406438405366276269243226191180
SPRAVATO (esketamine) — U.S. operational growth YoY (%)(%)
37.9%40.7%47.0%63.0%67.1%61.1%45.0%50.1%56.8%57.9%71.5%72.3%
SPRAVATO (esketamine) — International sales ($M)($M)1
667061645350432842443426
SPRAVATO (esketamine) — International operational growth YoY (%)(%)
21.4%34.7%28.7%23.8%11.0%31.7%12.5%47.4%77.4%74.8%83.4%
SPRAVATO (esketamine) — Worldwide reported growth YoY (%)(%)
36.1%40.8%46.4%69.0%61.5%53.3%41.9%44.6%54.9%60.2%72.2%74.1%
SPRAVATO (esketamine) — Worldwide operational (constant-currency) growth YoY (%)(%)1
36.0%40.0%44.5%67.8%60.8%53.0%42.9%45.3%55.3%60.8%72.0%73.6%
SPRAVATO (esketamine) — Worldwide currency (FX) impact YoY (%)(%)
0.1%0.8%1.9%1.2%0.7%0.3%-1.0%-0.7%-0.4%-0.6%0.2%0.5%
CAPLYTA (lumateperone) — Worldwide sales ($M)($M)2
3983612702492402110000
CAPLYTA (lumateperone) — U.S. sales ($M)($M)
3983612702492402110000
CAPLYTA (lumateperone) — International sales ($M)($M)
0000000000
CONCERTA / methylphenidate — Worldwide sales ($M)($M)4
143146136132140164148159142163177180
CONCERTA / methylphenidate — U.S. sales ($M)($M)1
6122261424383326344139
CONCERTA / methylphenidate — U.S. operational growth YoY (%)(%)
-56.3%-48.6%-43.4%-79.6%-49.2%-27.7%-7.4%-12.8%-55.0%-47.7%-41.2%5.7%
CONCERTA / methylphenidate — International sales ($M)($M)1
138133115126127139110125117129136142
CONCERTA / methylphenidate — International operational growth YoY (%)(%)
8.9%-4.8%-0.6%-1.4%8.5%7.0%-15.2%-7.7%-8.5%-4.6%4.5%9.2%
CONCERTA / methylphenidate — Worldwide reported growth YoY (%)(%)
2.1%-10.8%-8.0%-17.1%-1.4%0.2%-16.3%-11.7%-24.8%-21.5%-14.1%7.4%
CONCERTA / methylphenidate — Worldwide operational (constant-currency) growth YoY (%)(%)1
2.9%-11.3%-11.7%-17.8%-1.8%-0.2%-13.4%-8.8%-22.5%-17.9%-11.1%8.5%
CONCERTA / methylphenidate — Worldwide currency (FX) impact YoY (%)(%)
-0.8%0.5%3.7%0.7%0.4%0.4%-2.9%-2.9%-2.3%-3.6%-3.0%-1.1%
Other Neuroscience medicines — Worldwide sales ($M)($M)4
212232262245256270277255281294345404
Other Neuroscience medicines — U.S. sales ($M)($M)1
323438404645284946575871
Other Neuroscience medicines — U.S. operational growth YoY (%)(%)
-30.6%-22.9%32.6%-18.3%0.4%-23.5%-50.6%-31.0%-51.4%-42.5%-31.1%-23.0%
Other Neuroscience medicines — International sales ($M)($M)1
180198224205210226248206235237287334
Other Neuroscience medicines — International operational growth YoY (%)(%)
-13.1%-13.7%-16.3%-4.3%-12.3%-7.6%-9.8%-35.4%-2.0%-10.8%-8.4%3.2%
Other Neuroscience medicines — Worldwide reported growth YoY (%)(%)
-17.3%-14.0%-5.4%-4.1%-8.9%-8.4%-19.6%-36.9%-17.4%-23.7%-18.5%-8.7%
Other Neuroscience medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1
-16.2%-15.2%-11.3%-6.9%-10.2%-10.7%-16.7%-34.6%-15.7%-19.1%-12.9%-2.3%
Other Neuroscience medicines — Worldwide currency (FX) impact YoY (%)(%)
-1.1%1.2%5.9%2.8%1.3%2.3%-2.9%-2.3%-1.7%-4.6%-5.6%-6.4%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M)($M)7
8971,1431,1351,1841,1151,1131,0251,0921,1021,0391,0491,017
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. sales ($M)($M)1
588814831865815799744819815743766733
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. operational growth YoY (%)(%)
-27.8%1.8%11.7%5.7%-0.1%7.6%-2.9%11.6%20.0%8.7%27.5%20.2%
Pulmonary Hypertension (PH) Therapeutic Area Total — International sales ($M)($M)1
309329304319300314281274287296283282
Pulmonary Hypertension (PH) Therapeutic Area Total — International operational growth YoY (%)(%)
4.1%3.4%1.0%12.2%2.0%2.8%3.2%1.2%9.7%11.2%10.9%10.9%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
-19.5%2.6%10.7%8.4%1.1%7.1%-2.3%7.4%15.6%6.9%20.2%16.7%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
-19.2%2.2%8.7%7.4%0.4%6.2%-1.2%8.7%17.0%9.4%22.4%17.4%
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.3%0.4%2.0%1.0%0.7%0.9%-1.1%-1.3%-1.4%-2.5%-2.2%-0.7%
UPTRAVI (selexipag) — Worldwide sales ($M)($M)4
483494483491484476451465458426468419
UPTRAVI (selexipag) — U.S. sales ($M)($M)1
383386385397392382365391379349392348
UPTRAVI (selexipag) — U.S. operational growth YoY (%)(%)
-2.2%1.0%5.4%1.6%3.5%9.4%-6.9%12.3%12.7%3.3%29.0%24.3%
UPTRAVI (selexipag) — International sales ($M)($M)1
10010898949294867580767670
UPTRAVI (selexipag) — International operational growth YoY (%)(%)
8.4%10.1%5.1%20.8%12.0%19.8%17.5%11.2%28.2%34.4%38.6%31.4%
UPTRAVI (selexipag) — Worldwide reported growth YoY (%)(%)
-0.1%3.8%7.1%5.7%5.6%11.7%-3.6%11.2%14.2%6.6%29.2%24.6%
UPTRAVI (selexipag) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-0.2%2.8%5.4%4.7%5.0%11.3%-2.9%12.1%15.2%8.1%30.5%25.4%
UPTRAVI (selexipag) — Worldwide currency (FX) impact YoY (%)(%)
0.1%1.0%1.7%1.0%0.6%0.4%-0.7%-0.9%-1.0%-1.5%-1.3%-0.8%
OPSUMIT / OPSYNVI (macitentan) — Worldwide sales ($M)($M)4
372602606643578582522570583548524536
OPSUMIT / OPSYNVI (macitentan) — U.S. sales ($M)($M)1
193416433458409403363408417376356368
OPSUMIT / OPSYNVI (macitentan) — U.S. operational growth YoY (%)(%)
-52.8%3.2%19.3%11.9%-1.6%6.9%2.1%4.8%25.4%13.7%30.4%20.5%
OPSUMIT / OPSYNVI (macitentan) — International sales ($M)($M)1
179187172185168180159162166171169169
OPSUMIT / OPSYNVI (macitentan) — International operational growth YoY (%)(%)
7.8%3.6%1.7%10.9%-1.8%2.1%-2.5%-2.5%1.7%0.5%4.6%8.3%
OPSUMIT / OPSYNVI (macitentan) — Worldwide reported growth YoY (%)(%)
-35.7%3.4%16.1%12.7%-0.8%6.4%-0.5%1.7%16.8%7.1%19.1%16.2%
OPSUMIT / OPSYNVI (macitentan) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-35.2%3.3%14.0%11.6%-1.7%5.4%0.6%2.5%17.4%9.1%20.6%16.3%
OPSUMIT / OPSYNVI (macitentan) — Worldwide currency (FX) impact YoY (%)(%)
-0.5%0.1%2.1%1.1%0.9%1.0%-1.1%-0.8%-0.6%-2.0%-1.5%-0.1%
Other Pulmonary Hypertension medicines — Worldwide sales ($M)($M)4
424746495355525760675661
Other Pulmonary Hypertension medicines — U.S. sales ($M)($M)1
121312101316151921171818
Other Pulmonary Hypertension medicines — U.S. operational growth YoY (%)(%)
-7.3%-16.9%-21.1%-43.7%-36.5%-12.4%-12.7%54.0%18.8%-24.6%-29.4%
Other Pulmonary Hypertension medicines — International sales ($M)($M)1
303434393940373839493945
Other Pulmonary Hypertension medicines — International operational growth YoY (%)(%)
-21.2%-12.7%-11.8%1.2%-2.5%-21.3%-0.3%-0.4%12.4%21.0%-1.0%-3.9%
Other Pulmonary Hypertension medicines — Worldwide reported growth YoY (%)(%)
-19.7%-15.0%-12.1%-12.5%-13.1%-16.9%-7.2%32.3%15.0%7.2%-19.5%-16.2%
Other Pulmonary Hypertension medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1
-17.7%-13.9%-14.5%-13.5%-14.1%-19.0%-4.3%39.3%25.9%20.4%-8.9%-12.4%
Other Pulmonary Hypertension medicines — Worldwide currency (FX) impact YoY (%)(%)
-2.0%-1.1%2.4%1.0%1.0%2.1%-2.9%-7.0%-10.9%-13.2%-10.6%-3.8%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M)($M)8
813763889807829803802774836965821852
Infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M)($M)1
317300342303326320315331365334324353
Infectious Diseases (ID) Therapeutic Area Total — U.S. operational growth YoY (%)(%)
-2.7%-6.3%8.6%-8.5%-10.5%-4.3%-2.8%-6.4%1.5%-15.4%-17.4%-14.6%
Infectious Diseases (ID) Therapeutic Area Total — International sales ($M)($M)1
496463547505501484487443471631497498
Infectious Diseases (ID) Therapeutic Area Total — International operational growth YoY (%)(%)
-0.1%-6.2%1.3%5.6%0.5%-26.8%1.9%-9.8%-5.1%-11.6%-58.5%-58.2%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
-1.8%-5.0%10.8%4.3%-0.9%-16.8%-2.2%-9.2%-2.7%-13.9%-48.3%-44.7%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
-1.1%-6.3%4.1%-0.4%-4.3%-19.0%0.1%-8.4%-2.4%-12.9%-48.3%-46.5%
Infectious Diseases (ID) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.7%1.3%6.7%4.7%3.4%2.2%-2.3%-0.8%-0.3%-1.0%0.0%1.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide sales ($M)($M)4
381372443383397396403407449438418439
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. sales ($M)($M)1
307296334294315312305321355321314341
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. operational growth YoY (%)(%)
-2.5%-5.1%9.5%-8.4%-11.0%-3.0%-2.9%-5.8%2.8%-16.0%-16.9%-14.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International sales ($M)($M)1
747610989818598869411710498
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International operational growth YoY (%)(%)
-7.7%-12.8%0.7%-2.9%-18.5%-29.4%-0.6%-8.9%-3.0%9.9%5.5%-0.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%)(%)
-3.8%-6.3%10.0%-5.8%-11.6%-9.4%-3.7%-7.4%0.6%-11.0%-12.3%-11.0%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-3.6%-6.8%7.4%-7.2%-12.6%-10.0%-2.3%-6.5%1.5%-10.3%-12.3%-11.8%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide currency (FX) impact YoY (%)(%)
-0.2%0.5%2.6%1.4%1.0%0.6%-1.4%-0.9%-0.9%-0.7%0.0%0.8%
EDURANT / rilpivirine — Worldwide sales ($M)($M)4
386350409383385360358322330297323307
EDURANT / rilpivirine — U.S. sales ($M)($M)1
537576878889
EDURANT / rilpivirine — U.S. operational growth YoY (%)(%)
-31.6%-49.6%-13.1%-39.1%-7.9%-25.4%-1.3%-10.1%-15.8%-2.8%-10.9%-12.4%
EDURANT / rilpivirine — International sales ($M)($M)1
382347402379378354350315323288315299
EDURANT / rilpivirine — International operational growth YoY (%)(%)
2.4%-3.8%3.2%11.1%9.9%16.7%14.7%5.6%11.4%13.0%15.7%1.5%
EDURANT / rilpivirine — Worldwide reported growth YoY (%)(%)
0.4%-2.7%14.1%19.2%16.4%21.6%10.7%4.6%11.5%11.0%15.7%5.8%
EDURANT / rilpivirine — Worldwide operational (constant-currency) growth YoY (%)(%)1
1.8%-4.6%2.8%9.9%9.5%15.5%14.3%5.1%10.6%12.5%14.8%1.0%
EDURANT / rilpivirine — Worldwide currency (FX) impact YoY (%)(%)
-1.4%1.9%11.3%9.3%6.9%6.1%-3.6%-0.5%0.9%-1.5%0.9%4.8%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M)($M)4
011722544
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M)($M)
00000
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M)($M)1
011722544
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%)(%)
-98.9%-39.7%-96.7%-95.2%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%)(%)
-97.7%-39.7%-96.6%-93.7%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1
-98.9%-39.7%-96.7%-95.2%
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide currency (FX) impact YoY (%)(%)
1.2%0.0%0.1%1.5%
Other Infectious Diseases medicines — Worldwide sales ($M)($M)4
464137404747414556233781,179
Other Infectious Diseases medicines — U.S. sales ($M)($M)1
511442213524
Other Infectious Diseases medicines — U.S. operational growth YoY (%)(%)
29.9%-47.9%-56.9%92.9%57.3%-51.8%7.7%-53.1%-52.2%18.5%-68.8%-30.4%
Other Infectious Diseases medicines — International sales ($M)($M)1
404036374245394354227771,175
Other Infectious Diseases medicines — International operational growth YoY (%)(%)
-7.9%-12.8%-14.7%-18.0%-22.3%-80.6%-47.0%-22.4%-20.5%-21.1%-30.6%-4.9%
Other Infectious Diseases medicines — Worldwide reported growth YoY (%)(%)
-3.0%-11.6%-10.4%-9.9%-17.5%-79.8%-47.6%-26.1%-25.4%-23.1%-35.1%-7.8%
Other Infectious Diseases medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1
-4.5%-14.6%-16.5%-13.2%-18.5%-79.9%-45.9%-24.4%-22.9%-18.8%-33.1%-7.1%
Other Infectious Diseases medicines — Worldwide currency (FX) impact YoY (%)(%)
1.5%3.0%6.1%3.3%1.0%0.1%-1.7%-1.7%-2.5%-4.3%-2.0%-0.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M)($M)6
8498898769368999301,013957884892829837
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. sales ($M)($M)1
736765734794750776855805713717631652
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. operational growth YoY (%)(%)
-1.9%-1.3%-14.2%-1.4%5.3%8.2%35.4%23.3%-6.5%-7.7%-11.7%-15.9%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International sales ($M)($M)1
112124142142149154158153170176197185
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International operational growth YoY (%)(%)
-23.8%-21.5%-17.5%-10.7%-15.6%-13.2%-15.3%-15.1%-10.0%4.0%-6.8%-6.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide reported growth YoY (%)(%)
-5.6%-4.3%-13.6%-2.2%1.7%4.2%22.3%14.3%-7.6%-6.2%-10.6%-13.7%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
-5.5%-4.7%-14.7%-2.9%1.2%4.0%23.4%14.8%-7.2%-5.5%-10.5%-14.1%
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%)
-0.1%0.4%1.1%0.7%0.5%0.2%-1.1%-0.5%-0.4%-0.7%-0.1%0.4%
XARELTO (rivaroxaban) — Worldwide sales ($M)($M)4
653664642687635621690676592587518525
XARELTO (rivaroxaban) — U.S. sales ($M)($M)1
653664642687635621690676592587518525
XARELTO (rivaroxaban) — U.S. operational growth YoY (%)(%)
2.7%7.1%-7.0%1.7%7.4%5.6%33.3%28.5%-5.2%-7.9%-10.4%-21.2%
XARELTO (rivaroxaban) — International sales ($M)($M)1
000000000000
XARELTO (rivaroxaban) — International operational growth YoY (%)(%)
-23.8%-21.5%-17.5%-10.7%-15.6%-13.2%-15.3%-15.1%-10.0%4.0%-6.8%-6.7%
XARELTO (rivaroxaban) — Worldwide reported growth YoY (%)(%)
2.7%7.1%-7.0%1.7%7.4%5.6%33.3%28.5%-5.2%-7.9%-10.4%-21.2%
XARELTO (rivaroxaban) — Worldwide operational (constant-currency) growth YoY (%)(%)1
2.7%7.1%-7.0%1.7%7.4%5.6%33.3%28.5%-5.2%-7.9%-10.4%-21.2%
XARELTO (rivaroxaban) — Worldwide currency (FX) impact YoY (%)(%)
-0.2%1.1%3.4%2.4%1.5%0.5%-2.8%-1.5%-1.1%-1.9%-0.1%1.3%
Other Cardiovascular / Metabolism / Other medicines — Worldwide sales ($M)($M)2
197225233249264309323281292305311312
Other Cardiovascular / Metabolism / Other medicines — U.S. sales ($M)($M)
8410191107115155165130121129114127
Other Cardiovascular / Metabolism / Other medicines — International sales ($M)($M)
112124142142149154158153170176197185
MedTech Segment Total — Worldwide sales ($M)($M)9
8,6428,9268,6368,8018,4308,5418,0208,1887,8917,9577,8217,673
MedTech Segment Total — U.S. sales ($M)($M)1
4,5124,5544,4594,5064,3064,3834,2134,2274,0384,0594,0083,930
MedTech Segment Total — U.S. operational growth YoY (%)(%)
4.8%3.9%5.9%6.6%6.6%8.0%5.1%7.6%7.8%5.7%6.6%14.1%
MedTech Segment Total — International sales ($M)($M)1
4,1304,3724,1774,2954,1244,1583,8073,9613,8533,8983,8133,743
MedTech Segment Total — International operational growth YoY (%)(%)
0.1%3.2%3.2%4.9%4.5%4.1%3.0%7.6%5.0%3.2%6.1%12.8%
MedTech Segment Total — Worldwide reported growth YoY (%)(%)
2.5%4.5%7.7%7.5%6.8%7.3%2.5%6.7%5.8%2.2%4.5%13.3%
MedTech Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1
2.5%3.6%4.6%5.8%5.6%6.1%4.1%7.6%6.4%4.4%6.3%13.4%
MedTech Segment Total — Worldwide currency (FX) impact YoY (%)(%)
0.0%0.9%3.1%1.7%1.2%1.2%-1.6%-0.9%-0.6%-2.2%-1.8%-0.1%
MedTech — Worldwide adjusted operational growth ex-A&D YoY (%)(%)
2.5%3.7%4.7%5.9%5.7%4.1%1.3%4.6%3.7%4.0%6.5%9.1%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M)($M)8
2,3072,4042,3772,2992,2132,3132,1032,0621,9661,8731,8061,669
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. sales ($M)($M)1
1,3971,4261,3991,3741,3061,3641,2611,2211,1481,1191,025971
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. operational growth YoY (%)(%)
7.0%4.5%10.9%12.5%13.8%21.9%23.0%25.8%28.6%23.3%18.8%61.0%
Cardiovascular (formerly Interventional Solutions) Franchise — International sales ($M)($M)1
910978978925908948842841819753781698
Cardiovascular (formerly Interventional Solutions) Franchise — International operational growth YoY (%)(%)
-0.2%1.1%9.9%6.8%8.4%22.9%10.7%22.0%23.7%11.2%27.6%41.7%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%)(%)
4.3%4.0%13.0%11.5%12.6%23.5%16.4%23.6%26.2%15.6%20.2%51.9%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
4.1%3.1%10.5%10.1%11.6%22.3%17.7%24.2%26.5%18.0%22.5%52.3%
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide currency (FX) impact YoY (%)(%)
0.2%0.9%2.5%1.4%1.0%1.2%-1.3%-0.6%-0.3%-2.4%-2.3%-0.4%
Electrophysiology sub-franchise — Worldwide sales ($M)($M)4
1,4871,5331,4891,4251,4181,4681,3231,3211,2791,3231,3441,239
Electrophysiology sub-franchise — U.S. sales ($M)($M)1
771783736746720741684681660705692667
Electrophysiology sub-franchise — U.S. operational growth YoY (%)(%)
7.0%5.8%7.6%9.5%9.1%5.1%-1.1%2.1%7.9%15.7%21.3%22.0%
Electrophysiology sub-franchise — International sales ($M)($M)1
717749753679698728638640619618652572
Electrophysiology sub-franchise — International operational growth YoY (%)(%)
1.8%0.4%11.7%3.2%10.4%15.2%0.7%13.3%13.8%11.1%30.9%29.0%
Electrophysiology sub-franchise — Worldwide reported growth YoY (%)(%)
4.9%4.4%12.6%7.9%10.8%11.0%-1.6%6.6%10.2%10.6%23.0%24.7%
Electrophysiology sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
4.4%3.1%9.5%6.5%9.7%9.8%-0.2%7.3%10.7%13.4%25.9%25.2%
Electrophysiology sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
0.5%1.3%3.1%1.4%1.1%1.2%-1.4%-0.7%-0.5%-2.8%-2.9%-0.5%
Abiomed (Impella heart pumps) sub-franchise — Worldwide sales ($M)($M)4
412440488460423448420384362379371340
Abiomed (Impella heart pumps) sub-franchise — U.S. sales ($M)($M)1
335342389358336360339308293309303276
Abiomed (Impella heart pumps) sub-franchise — U.S. operational growth YoY (%)(%)
-0.3%-4.8%14.5%16.5%14.5%16.6%11.9%11.3%15.4%13.2%15.0%8.8%
Abiomed (Impella heart pumps) sub-franchise — International sales ($M)($M)1
78971001028689817768726764
Abiomed (Impella heart pumps) sub-franchise — International operational growth YoY (%)(%)
-6.5%9.2%13.9%25.4%20.2%18.4%23.6%21.1%20.1%25.3%14.7%27.1%
Abiomed (Impella heart pumps) sub-franchise — Worldwide reported growth YoY (%)(%)
-2.3%-2.0%16.3%19.8%16.8%18.2%13.3%12.9%16.3%14.5%14.5%20.4%
Abiomed (Impella heart pumps) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
-1.5%-2.0%14.4%18.3%15.6%16.9%14.0%13.2%16.3%15.4%15.0%20.7%
Abiomed (Impella heart pumps) sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.8%0.0%1.9%1.5%1.2%1.3%-0.7%-0.3%0.0%-0.9%-0.5%-0.3%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M)($M)4
3253353053182782922582582297700
Shockwave (intravascular lithotripsy) sub-franchise — U.S. sales ($M)($M)1
2612682422382202332062021637700
Shockwave (intravascular lithotripsy) sub-franchise — U.S. operational growth YoY (%)(%)
18.8%14.6%17.8%18.0%34.4%
Shockwave (intravascular lithotripsy) sub-franchise — International sales ($M)($M)1
646763805958525666000
Shockwave (intravascular lithotripsy) sub-franchise — International operational growth YoY (%)(%)
11.2%15.4%19.3%40.7%-12.4%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide reported growth YoY (%)(%)
16.8%14.6%18.5%23.3%21.2%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
17.2%14.7%18.1%22.9%20.9%
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.4%-0.1%0.4%0.4%0.3%
Other Cardiovascular sub-franchise — Worldwide sales ($M)($M)4
81989495951041039996939289
Other Cardiovascular sub-franchise — U.S. sales ($M)($M)1
313332313031323130293028
Other Cardiovascular sub-franchise — U.S. operational growth YoY (%)(%)
3.6%5.5%0.7%-0.1%0.0%5.4%7.1%11.1%16.7%12.5%3.3%
Other Cardiovascular sub-franchise — International sales ($M)($M)1
506562646572726866646261
Other Cardiovascular sub-franchise — International operational growth YoY (%)(%)
-23.1%-13.2%-17.5%-8.8%-2.5%11.6%17.4%12.3%7.5%-1.0%11.5%
Other Cardiovascular sub-franchise — Worldwide reported growth YoY (%)(%)
-13.9%-5.7%-9.1%-4.6%-0.7%10.8%12.5%11.8%10.4%0.3%5.7%
Other Cardiovascular sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
-14.7%-7.5%-11.9%-6.1%-1.7%9.7%14.1%12.0%10.2%2.8%8.8%
Other Cardiovascular sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
0.8%1.8%2.8%1.5%1.0%1.1%-1.6%-0.2%0.2%-2.5%-3.1%
Surgery Franchise — Worldwide sales ($M)($M)6
2,5282,6532,5112,6442,5422,5552,3962,5072,4342,4882,4162,530
Surgery Franchise — U.S. sales ($M)($M)1
1,0701,0941,0461,0811,0311,0431,0021,0389839959871,047
Surgery Franchise — U.S. operational growth YoY (%)(%)
3.7%5.0%4.4%4.2%4.9%4.8%1.5%-0.9%-1.1%-2.0%1.2%4.6%
Surgery Franchise — International sales ($M)($M)1
1,4591,5591,4651,5631,5111,5121,3941,4691,4511,4931,4291,484
Surgery Franchise — International operational growth YoY (%)(%)
-4.2%0.5%-1.1%3.4%2.2%-0.2%0.8%1.4%-0.3%-0.7%2.3%7.8%
Surgery Franchise — Worldwide reported growth YoY (%)(%)
-0.6%3.9%4.8%5.5%4.4%2.7%-0.8%-0.9%-1.8%-4.1%-0.7%6.1%
Surgery Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
-1.0%2.3%1.2%3.7%3.3%1.8%1.1%0.4%-0.7%-1.2%1.9%6.4%
Surgery Franchise — Worldwide currency (FX) impact YoY (%)(%)
0.4%1.6%3.6%1.8%1.1%0.9%-1.9%-1.3%-1.1%-2.9%-2.6%-0.3%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide sales ($M)($M)4
1,1551,1891,1231,1751,1651,1641,0731,1511,1091,1411,0871,167
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. sales ($M)($M)1
500499477489477477457478448466446468
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. operational growth YoY (%)(%)
5.1%4.7%4.2%2.5%6.2%2.2%2.7%2.0%-1.4%0.1%0.2%2.5%
Advanced Surgery (endocutters, energy, biosurgicals) — International sales ($M)($M)1
654691646687688687616673661675641698
Advanced Surgery (endocutters, energy, biosurgicals) — International operational growth YoY (%)(%)
-5.7%-1.9%-1.0%-0.8%2.1%0.2%-1.0%-1.6%-5.1%-6.4%-0.7%7.2%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide reported growth YoY (%)(%)
-0.9%2.2%4.6%2.2%5.0%2.0%-1.2%-1.4%-4.7%-6.7%-2.8%5.1%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-1.3%0.8%1.2%0.6%3.8%1.0%0.5%-0.1%-3.6%-3.9%-0.3%5.2%
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide currency (FX) impact YoY (%)(%)
0.4%1.4%3.4%1.6%1.2%1.0%-1.7%-1.3%-1.1%-2.8%-2.5%-0.1%
General Surgery (wound closure / sutures) — Worldwide sales ($M)($M)4
1,3731,4641,3881,4681,3781,3911,3231,3571,3251,3461,3301,364
General Surgery (wound closure / sutures) — U.S. sales ($M)($M)1
568596569592555567544560535528542579
General Surgery (wound closure / sutures) — U.S. operational growth YoY (%)(%)
2.4%5.2%4.5%5.6%3.8%7.2%0.5%-3.1%-0.9%-3.7%2.1%6.4%
General Surgery (wound closure / sutures) — International sales ($M)($M)1
805868819876823825778795791818788785
General Surgery (wound closure / sutures) — International operational growth YoY (%)(%)
-3.0%2.5%-1.3%6.9%2.2%-0.6%2.3%4.0%4.0%4.5%4.8%8.3%
General Surgery (wound closure / sutures) — Worldwide reported growth YoY (%)(%)
-0.3%5.2%4.9%8.3%3.9%3.3%-0.5%-0.5%0.8%-1.9%1.0%7.0%
General Surgery (wound closure / sutures) — Worldwide operational (constant-currency) growth YoY (%)(%)1
-0.8%3.6%1.1%6.3%2.9%2.5%1.6%1.0%2.0%1.2%3.7%7.5%
General Surgery (wound closure / sutures) — Worldwide currency (FX) impact YoY (%)(%)
0.5%1.6%3.8%2.0%1.0%0.8%-2.1%-1.5%-1.2%-3.1%-2.7%-0.5%
Orthopaedics Franchise — Worldwide sales ($M)($M)8
2,3452,4182,3832,4382,2742,3052,2412,3152,1912,3122,3402,268
Orthopaedics Franchise — U.S. sales ($M)($M)1
1,4481,4701,4351,5201,3961,4201,3841,4601,3591,4221,4481,425
Orthopaedics Franchise — U.S. operational growth YoY (%)(%)
3.8%3.5%3.7%4.2%2.7%-0.2%-4.4%2.4%0.7%2.5%6.2%2.9%
Orthopaedics Franchise — International sales ($M)($M)1
898948948918878885857856832890892843
Orthopaedics Franchise — International operational growth YoY (%)(%)
2.9%5.3%2.4%2.3%1.9%-4.0%-0.9%2.5%2.2%4.5%2.7%8.8%
Orthopaedics Franchise — Worldwide reported growth YoY (%)(%)
3.2%4.9%6.3%5.3%3.8%-0.3%-4.2%2.1%1.2%2.1%4.3%5.6%
Orthopaedics Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
3.4%4.2%3.2%3.5%2.4%-1.6%-3.1%2.5%1.3%3.3%4.8%5.0%
Orthopaedics Franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.2%0.7%3.1%1.8%1.4%1.3%-1.1%-0.4%-0.1%-1.2%-0.5%0.6%
Hips reconstructive sub-franchise — Worldwide sales ($M)($M)4
419441436439405421409418381417422398
Hips reconstructive sub-franchise — U.S. sales ($M)($M)1
271283277284262271263272250265270266
Hips reconstructive sub-franchise — U.S. operational growth YoY (%)(%)
3.5%4.6%5.2%4.3%4.7%2.1%-2.5%2.5%4.8%5.8%12.1%6.3%
Hips reconstructive sub-franchise — International sales ($M)($M)1
148158159154144150146146131152152132
Hips reconstructive sub-franchise — International operational growth YoY (%)(%)
3.0%3.0%0.3%0.4%5.9%-4.3%-0.8%11.7%-3.2%6.8%3.3%-3.9%
Hips reconstructive sub-franchise — Worldwide reported growth YoY (%)(%)
3.1%4.9%6.5%4.7%6.4%1.0%-3.1%5.2%1.7%4.9%8.1%3.4%
Hips reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
3.3%4.0%3.5%2.9%5.1%-0.2%-1.9%5.6%1.9%6.2%8.7%2.7%
Hips reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.2%0.9%3.0%1.8%1.3%1.2%-1.2%-0.4%-0.2%-1.3%-0.6%0.7%
Knees reconstructive sub-franchise — Worldwide sales ($M)($M)4
386410420432377389389398352394401387
Knees reconstructive sub-franchise — U.S. sales ($M)($M)1
221228239251216226231238212230242242
Knees reconstructive sub-franchise — U.S. operational growth YoY (%)(%)
2.1%1.1%3.3%5.1%2.1%-1.9%-4.3%-1.5%2.2%4.2%6.9%4.5%
Knees reconstructive sub-franchise — International sales ($M)($M)1
165182181181160164158160140163160144
Knees reconstructive sub-franchise — International operational growth YoY (%)(%)
4.4%10.3%6.5%9.2%10.9%-2.9%2.1%11.3%7.0%17.7%13.1%15.6%
Knees reconstructive sub-franchise — Worldwide reported growth YoY (%)(%)
2.5%5.5%7.9%8.6%7.0%-1.1%-3.0%3.1%4.0%8.4%9.0%9.2%
Knees reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
3.1%5.0%4.6%6.8%5.6%-2.3%-1.7%3.3%4.1%9.5%9.3%8.4%
Knees reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.6%0.5%3.3%1.8%1.4%1.2%-1.3%-0.2%-0.1%-1.1%-0.3%0.8%
Trauma extremities sub-franchise — Worldwide sales ($M)($M)4
844827833813793768772764761759765741
Trauma extremities sub-franchise — U.S. sales ($M)($M)1
555536532543512501502514497498504487
Trauma extremities sub-franchise — U.S. operational growth YoY (%)(%)
8.6%6.7%6.1%5.6%3.0%0.7%-0.5%5.5%1.8%3.0%2.8%3.6%
Trauma extremities sub-franchise — International sales ($M)($M)1
288291301270281267270250265260261255
Trauma extremities sub-franchise — International operational growth YoY (%)(%)
2.8%7.4%3.1%2.7%2.5%-1.5%7.2%-0.5%4.8%5.5%-1.1%4.1%
Trauma extremities sub-franchise — Worldwide reported growth YoY (%)(%)
6.4%7.6%8.0%6.4%4.2%1.2%0.9%3.0%2.6%2.8%1.0%4.4%
Trauma extremities sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
6.5%6.9%5.0%4.7%2.9%-0.1%2.1%3.5%2.8%3.8%1.4%3.8%
Trauma extremities sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.1%0.7%3.0%1.7%1.3%1.3%-1.2%-0.5%-0.2%-1.0%-0.4%0.6%
Spine, Sports & Other sub-franchise — Worldwide sales ($M)($M)4
697740694756698727671735696743752742
Spine, Sports & Other sub-franchise — U.S. sales ($M)($M)1
401423387442406422388434400430432430
Spine, Sports & Other sub-franchise — U.S. operational growth YoY (%)(%)
-1.2%0.2%-0.1%1.9%1.3%-1.7%-10.2%1.1%-3.6%-0.8%6.5%-0.7%
Spine, Sports & Other sub-franchise — International sales ($M)($M)1
296317307312293305283300296314320311
Spine, Sports & Other sub-franchise — International operational growth YoY (%)(%)
2.0%1.9%0.7%-0.7%-4.8%-6.4%-8.9%-2.9%0.4%-2.9%0.9%16.5%
Spine, Sports & Other sub-franchise — Worldwide reported growth YoY (%)(%)
-0.1%1.8%3.5%2.8%0.3%-2.1%-10.8%-0.9%-1.9%-3.1%3.2%6.2%
Spine, Sports & Other sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
0.1%0.9%0.2%0.8%-1.3%-3.7%-9.7%-0.6%-2.0%-1.7%4.0%5.8%
Spine, Sports & Other sub-franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.2%0.9%3.3%2.0%1.6%1.6%-1.1%-0.3%0.1%-1.4%-0.8%0.4%
Vision Franchise — Worldwide sales ($M)($M)6
1,4611,4511,3651,4201,4001,3691,2791,3031,3001,2851,2581,208
Vision Franchise — U.S. sales ($M)($M)1
596565579531571557566509549523547487
Vision Franchise — U.S. operational growth YoY (%)(%)
4.3%1.4%2.4%4.3%4.2%6.5%3.4%4.5%7.2%-1.2%-1.8%6.8%
Vision Franchise — International sales ($M)($M)1
865887785889828813713794751763710721
Vision Franchise — International operational growth YoY (%)(%)
5.6%8.5%4.6%8.5%7.5%3.4%3.9%12.2%1.8%2.2%-1.1%6.4%
Vision Franchise — Worldwide reported growth YoY (%)(%)
4.4%6.0%6.7%8.9%7.7%6.5%1.7%7.9%3.5%-1.7%-3.3%5.5%
Vision Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1
5.1%5.6%3.6%6.8%6.1%4.6%3.7%9.1%4.0%0.8%-1.4%6.6%
Vision Franchise — Worldwide currency (FX) impact YoY (%)(%)
-0.7%0.4%3.1%2.1%1.6%1.9%-2.0%-1.2%-0.5%-2.5%-1.9%-1.1%
Contact Lenses / Other (ACUVUE) — Worldwide sales ($M)($M)4
1,0531,0259691,0081,018965919937968918910882
Contact Lenses / Other (ACUVUE) — U.S. sales ($M)($M)1
465445468417456429452396441409438374
Contact Lenses / Other (ACUVUE) — U.S. operational growth YoY (%)(%)
1.9%3.6%3.7%5.3%3.5%4.8%3.1%6.0%10.2%0.2%-1.4%8.9%
Contact Lenses / Other (ACUVUE) — International sales ($M)($M)1
588580501592562536467541527509472508
Contact Lenses / Other (ACUVUE) — International operational growth YoY (%)(%)
6.2%7.9%1.7%5.3%3.4%1.4%2.4%8.5%0.6%1.2%-3.1%7.2%
Contact Lenses / Other (ACUVUE) — Worldwide reported growth YoY (%)(%)
3.5%6.1%5.5%7.6%5.2%5.1%1.0%6.3%4.2%-2.2%-4.6%6.1%
Contact Lenses / Other (ACUVUE) — Worldwide operational (constant-currency) growth YoY (%)(%)1
4.3%6.0%2.7%5.3%3.5%2.9%2.7%7.4%4.7%0.7%-2.3%7.9%
Contact Lenses / Other (ACUVUE) — Worldwide currency (FX) impact YoY (%)(%)
-0.8%0.1%2.8%2.3%1.7%2.2%-1.7%-1.1%-0.5%-2.9%-2.3%-1.8%
Surgical Vision (intraocular lenses / cataract) — Worldwide sales ($M)($M)4
408426396411383403361365333367348326
Surgical Vision (intraocular lenses / cataract) — U.S. sales ($M)($M)1
132120111113116128114113108113110114
Surgical Vision (intraocular lenses / cataract) — U.S. operational growth YoY (%)(%)
13.6%-6.0%-2.9%0.6%7.0%12.6%4.3%-0.4%-3.6%-5.8%-3.7%0.4%
Surgical Vision (intraocular lenses / cataract) — International sales ($M)($M)1
276306285297266277246252225254238212
Surgical Vision (intraocular lenses / cataract) — International operational growth YoY (%)(%)
4.3%9.6%10.1%15.3%17.1%7.3%7.1%21.1%4.7%4.5%3.4%4.7%
Surgical Vision (intraocular lenses / cataract) — Worldwide reported growth YoY (%)(%)
6.8%5.6%9.7%12.4%14.9%9.9%3.7%12.4%1.3%-0.5%0.3%3.7%
Surgical Vision (intraocular lenses / cataract) — Worldwide operational (constant-currency) growth YoY (%)(%)1
7.1%4.7%6.0%10.8%13.8%8.9%6.2%13.6%1.9%1.2%1.1%3.1%
Surgical Vision (intraocular lenses / cataract) — Worldwide currency (FX) impact YoY (%)(%)
-0.3%0.9%3.7%1.6%1.1%1.0%-2.5%-1.2%-0.6%-1.7%-0.8%0.6%
Total segment income before tax ($M)($M)3
5,8427,4266,5565,2597,7336,7566,6314,0815,5416,5486,4894,642
Innovative Medicine segment income before tax ($M)($M)4
5,0666,2495,3175,0586,4465,5525,2104,0094,4825,4594,9694,238
Innovative Medicine — Cost of products sold ($M)($M)
4,4864,2964,3903,9763,6723,9784,0203,5143,5493,6033,370
Innovative Medicine — Selling, marketing and administrative expenses ($M)($M)
3,0353,1302,9183,4562,8692,7892,2613,3122,4912,6652,438
Innovative Medicine — Research and development expense ($M)($M)
3,8882,8752,8133,4662,9442,8692,5483,6984,2132,7222,896
Innovative Medicine — Other segment expense/(income), net ($M)($M)
282-166-12-193-36814-166-201-15541-111
MedTech segment income before tax ($M)($M)4
7761,1771,2392011,2871,2041,421721,0591,0891,520404
MedTech — Cost of products sold ($M)($M)
3,5973,7373,7013,9733,6123,6383,3263,5963,3813,2483,120
MedTech — Selling, marketing and administrative expenses ($M)($M)
3,0143,0692,9063,0352,8012,8622,6562,8362,7232,6712,582
MedTech — Research and development expense ($M)($M)
7647787147867286476771,600739718646
MedTech — Other segment expense/(income), net ($M)($M)
491165768062190-6084-11231-47
Consolidated earnings before provision for taxes on income ($M)($M)
346,7475,9904,9667,4936,49113,6313,8873,3385,7483,7144,826
Consolidated total assets ($M)($M)2
197,425201,061200,894199,210192,816193,389193,671180,104178,287181,088171,966167,558
Total segment identifiable assets ($M)($M)
165,158165,437164,297164,539160,924162,232143,838141,392133,034
General corporate / unallocated assets ($M)($M)
32,26735,62436,59734,67131,89231,15749,83338,71234,524
Additions to property, plant and equipment — Consolidated ($M)($M)4
1,3621,3211,0491,8371,1571,0437951,6121,029976807
Total segment additions to PP&E ($M)($M)
1,3031,2461,0171,7371,0821,0027561,553973902725
Innovative Medicine additions to PP&E ($M)($M)
704653508910479411276739418321232
MedTech additions to PP&E ($M)($M)
599593509827603591480814555581493
General corporate additions to PP&E ($M)($M)
59753210075413959567482
Depreciation and amortization — Consolidated ($M)($M)4
2,1171,9592,0042,0111,7771,9431,7721,8961,8461,7821,8151,843
Total segment depreciation and amortization ($M)($M)
2,0531,9041,9391,9411,7181,8831,7201,8341,7501,6561,757
Innovative Medicine depreciation and amortization ($M)($M)
8008001,0361,0156008008849677007001,0111,647
MedTech depreciation and amortization ($M)($M)
5005009039265005008368675004007461,843
General corporate depreciation and amortization ($M)($M)
64556570596052629612658
Goodwill — Consolidated carrying value ($M)($M)2
48,47448,47948,55848,77248,04848,11744,46844,20044,79944,25036,61636,558
Innovative Medicine goodwill ($M)($M)
14,74814,75514,81214,96714,26814,32610,90710,69211,11210,76810,55210,407
MedTech goodwill ($M)($M)
33,72633,72433,74633,80533,78033,79133,56133,50833,68733,48226,06426,151
Non-GAAP adjusted earnings before provision for taxes on income ($M)($M)2
7,6728,6607,8217,0468,4368,1888,0115,4217,2778,4047,8776,237
Non-GAAP adjusted pre-tax profit margin (% to sales)(%)
30.2%34.2%32.5%28.7%35.2%34.5%36.6%24.1%32.4%37.4%36.8%29.2%
Non-GAAP adjusted pre-tax earnings growth YoY (%)(%)
-9.1%5.8%-2.4%30.0%15.9%-2.6%1.7%-13.1%-9.4%5.0%4.5%-3.8%
Non-GAAP adjusted net earnings ($M)($M)5
6,3397,0816,6146,0096,8016,6996,7064,9465,8766,8406,5805,562
Non-GAAP adjusted net profit margin (% to sales)(%)
25.0%28.0%27.5%24.5%28.3%28.2%30.6%22.0%26.1%30.5%30.8%26.0%
Non-GAAP adjusted net earnings growth YoY (%)(%)
-6.8%5.7%-1.4%21.5%15.7%-2.1%1.9%-11.1%-13.3%1.6%3.8%2.4%
Pre-tax Non-GAAP adjustment — Intangible asset amortization expense ($M)($M)
1,2401,2451,2471,1861,0481,2671,1201,1711,1711,1061,0781,148
Pre-tax Non-GAAP adjustment — Litigation-related expense/(gain), net ($M)($M)
5,5192673308541557-6,966-162,3883522,726166
Pre-tax Non-GAAP adjustment — Restructuring-related expense ($M)($M)
1952766221016879556247-11171139
Non-GAAP adjusted diluted net earnings per share ($)($)2
2.592.902.702.462.802.772.772.042.422.822.712.29
Operational (constant-currency) adjusted diluted EPS ($)($)
2.612.862.572.352.722.712.812.052.412.822.722.28
Non-GAAP adjusted diluted EPS growth YoY (%)(%)
-7.5%4.7%-2.5%20.6%15.7%-1.8%2.2%-10.9%-9.0%10.2%12.4%11.7%
Non-GAAP adjusted effective tax rate (%)(%)1
17.4%18.2%15.4%14.7%19.4%18.2%16.3%8.8%19.3%18.6%16.5%10.8%
GAAP effective tax rate (%)(%)
-517.6%18.0%12.6%-3.0%31.2%14.7%19.3%11.7%19.3%18.5%12.4%14.4%
GAAP gross profit ($M)($M)6
17,30217,25915,95616,59616,69016,11514,53615,39215,50815,57814,87214,597
GAAP gross profit margin (% to sales)(%)
68.1%68.2%66.3%67.6%69.6%67.9%66.4%68.4%69.0%69.4%69.6%68.2%
Cost of products sold (% to sales)(%)
31.9%31.8%33.7%32.4%30.4%32.1%33.6%31.6%31.0%30.6%30.4%31.8%
Selling, marketing and administrative expenses (% to sales)(%)
24.7%25.4%25.1%27.5%24.7%24.8%23.3%28.6%24.3%25.3%24.6%27.1%
Research and development expense (% to sales)(%)
18.3%14.4%14.7%17.3%15.3%14.8%14.7%23.5%22.0%15.3%16.6%20.9%
GAAP earnings before provision for taxes (% to sales)(%)
0.1%26.7%24.9%20.2%31.2%27.3%62.3%17.3%14.9%25.6%17.4%22.6%
GAAP net earnings margin (% to sales)(%)
0.8%21.9%21.8%20.8%21.5%23.3%50.2%15.2%12.0%20.9%15.2%19.3%
Full-Year Guidance — Estimated reported sales midpoint ($B)4
101.20101.10100.80100.5093.7093.4091.4089.6088.6088.2088.2088.20
Full-Year Guidance — Estimated reported sales growth midpoint (%)(%)
7.4%7.3%7.0%6.7%5.7%5.4%3.1%1.0%5.4%5.0%5.0%5.0%
Full-Year Guidance — Operational sales midpoint ($B)
100.70100.60100.20100.0093.2092.9092.0091.3089.6089.4088.0088.60
Full-Year Guidance — Operational sales growth midpoint (%)(%)
6.9%6.8%6.4%6.2%5.1%4.8%3.8%3.0%6.6%6.4%5.8%5.5%
Full-Year Guidance — Adjusted operational sales growth ex-A&D midpoint (%)(%)
6.6%6.5%6.1%5.9%3.8%3.5%2.5%2.5%6.0%5.8%5.8%5.5%
Full-Year Guidance — Adjusted diluted EPS midpoint ($)($)3
11.1011.6811.5511.5310.8510.8510.6010.609.9310.0210.6510.65
Full-Year Guidance — Adjusted diluted EPS growth midpoint (%)(%)
2.9%8.2%7.1%6.9%8.7%8.7%6.2%6.2%0.1%1.0%7.4%7.4%
Full-Year Guidance — Adjusted operational diluted EPS midpoint ($)($)
1111.5811.4011.3810.6810.6810.6010.859.9110.0510.6810.65
Full-Year Guidance — Adjusted operational diluted EPS growth midpoint (%)(%)
2.0%7.3%5.7%5.5%7.0%7.0%6.2%8.7%0.1%1.3%7.7%7.4%
Accrued rebates, returns and promotions (GTN) liability on balance sheet ($M)($M)
18,93619,99018,39919,12421,35620,82318,78017,58018,43917,53916,18216,001
Restructuring expense ($M)($M)
1813432846364174241-1316456
Total inventories, net ($M)($M)3
15,37715,14414,58314,19114,14613,41212,65912,44412,60312,16911,38311,181
Raw materials and supplies ($M)($M)
2,4832,5152,6122,5302,5522,3892,3712,3372,5452,4072,3312,355
Goods in process ($M)($M)
3,9304,2244,0333,8283,7633,9713,2032,8152,9892,5562,1721,952
Finished goods ($M)($M)
8,9648,4057,9387,8337,8317,0527,0857,2927,0697,2066,8806,874
Property, plant and equipment, net ($M)($M)2
24,10423,58223,27023,16922,33821,94920,87120,51820,47919,74819,63219,898
Property, plant and equipment, gross ($M)($M)
55,47255,51854,69554,36453,37552,47249,88448,76849,27448,03547,58547,776
Less: Accumulated depreciation ($M)($M)
31,36831,93631,42531,19531,03730,52329,01328,25028,79528,28727,95327,878
Intangible assets, net (excluding goodwill) ($M)($M)3
46,65248,22949,06150,40348,73749,83536,75537,61839,49039,72534,28634,175
Finite-lived intangible assets, net ($M)2
Patents and trademarks, net ($M)($M)
25,89924,81525,57626,64922,68722,51617,84318,57118,22718,60314,37215,609
Other finite-lived intangibles, net ($M)($M)
5,6885,9496,1846,3636,4697,4236,6116,7667,2097,1587,1887,637
Finite-lived intangible assets, gross ($M)2
Patents and trademarks, gross ($M)($M)
60,57558,54258,51559,15654,02653,27245,59144,69544,92643,43839,19840,417
Other finite-lived intangibles, gross ($M)($M)
21,15321,28321,34021,36121,17921,91020,49320,31020,71520,17619,93020,322
Intangible asset amortization expense ($M)($M)4
1,2001,2001,2001,2001,0001,3001,1001,1001,2001,1001,1001,100
Estimated future intangible amortization — Year 1 ($M)($M)
4,4004,4004,4005,1004,0004,0003,4004,0003,9003,9003,5004,300
Estimated future intangible amortization — Year 2 ($M)($M)
3,7003,7003,7004,4003,3003,4002,8003,4003,3003,3002,9003,500
Estimated future intangible amortization — Year 3 ($M)($M)
3,6003,6003,6003,7002,6002,7002,2002,8002,7002,7002,3002,900
Estimated future intangible amortization — Year 4 ($M)($M)
3,5003,5003,5003,6002,5002,6002,2002,2002,0002,0001,6002,300
Total long-term debt (including current maturities) ($M)1
Long-term debt, noncurrent ($M)($M)
35,79937,34437,52739,43839,40839,23538,35530,65131,28931,63625,08225,881
Cash dividends paid to shareholders ($M)($M)4
3,2273,2273,1313,1313,1323,1292,9892,9842,9852,9852,8692,865
Cash dividends paid per share ($)($)
1.341.341.301.301.301.241.241.241.19
Common stock repurchases ($M)($M)
1,712219-4,0341,9221,904-22,1292575391361,475216
Treasury stock shares held (M shares)
712.73711.62713.26711.90713.65713.06714.22712.92712.54713.00713.12712.76
Treasury stock carrying value ($M)($M)
76,18475,86376,26475,62475,88775,71375,90675,68075,61975,68975,71075,662
Stock-based compensation expense ($M)($M)
357458300355347410288262295341302116
U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (PCU325412325412)2
929.06926.72925.44919.12917.42915.09915.34918.11917.27914.37907.84896.32
U.S. Consumer Price Index (CPI) — Medical Care Commodities (CUSR0000SAM1)
404.94410.39416.81417.00416.48415.97412.57415.90414.52408.35410.06
U.S. Consumer Price Index (CPI) — Medical Care Services (CUUR0000SAM2)
654.45651.42648.16638.15631.04623.98618.85612.81611.70606.32597.15

135 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Johnson & Johnson operates on a 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q1 2026 ended March 29, 2026; Q2 2026 ended June 28, 2026; Q3 2026 ended September 27, 2026).
  • Core operational & financial KPIs (Groups 1–6) cover: (1) Consolidated & Geographic Revenue Disaggregation ($25,399M in Q3 2026 / $94,193M in FY25 across U.S. $14,959M and International $10,440M [Europe $5,405M, Asia-Pacific/Africa $3,650M, Western Hemisphere ex-U.S. $1,385M]) and Reported (+5.9%), Operational Constant-Currency (+6.0%), Currency FX (-0.1%), and Adjusted Operational ex-A&D (+6.1%) growth drivers across all regions; (2–3) Innovative Medicine Segment ($16,757M in Q3 2026 / $60,401M in FY25, +7.9% operational in Q3 2026) across all 6 Therapeutic Areas — Oncology ($7,602M in Q3 2026, +16.7% operational: DARZALEX $4,239M, ERLEADA $1,023M, CARVYKTI $710M, IMBRUVICA $563M, RYBREVANT/LAZCLUZE $320M, TECVAYLI $312M, TALVEY $171M, legacy ZYTIGA & VELCADE), Immunology ($4,221M: TREMFYA $2,396M, STELARA $716M, SIMPONI/SIMPONI ARIA $568M, REMICADE $394M including U.S. Exports), Neuroscience ($2,375M: INVEGA SUSTENNA/TRINZA $998M, SPRAVATO $624M, CAPLYTA $398M, CONCERTA $143M, legacy RISPERDAL CONSTA), Pulmonary Hypertension ($897M: UPTRAVI $483M, OPSUMIT/OPSYNVI $372M, legacy TRACLEER), Infectious Diseases ($813M: EDURANT $386M, PREZISTA/SYMTUZA $381M, legacy COVID-19 Vaccine), and Cardiovascular/Metabolism ($849M: XARELTO $653M, legacy INVOKANA & PROCRIT/EPREX) — each disaggregated by Worldwide, U.S., and International ($M and operational YoY %); (4) MedTech Segment ($8,642M in Q3 2026 / $33,792M in FY25, +2.5% operational) across Cardiovascular ($2,307M: Electrophysiology $1,487M, Abiomed $412M, Shockwave $325M), Surgery ($2,528M: Advanced $1,155M, General $1,373M), Orthopaedics ($2,345M: Trauma $844M, Spine/Sports & Other $697M, Hips $419M, Knees $386M), and Vision ($1,461M: Contact Lenses $1,053M, Surgical $408M), plus legacy Consumer Health franchises prior to the FY23Q3 Kenvue separation; (5) Segment Pre-Tax Income, Significant Segment Expenses under ASU 2023-07 (COGS, SM&A, R&D, Other), Identifiable Assets, CapEx, D&A, and Goodwill; and (6) Non-GAAP Adjusted Pre-Tax Profit ($7,672M / 30.2% margin in Q3 2026), Adjusted Net Earnings ($6,339M / 25.0% margin), Adjusted Diluted EPS ($2.59 in Q3 2026; $10.79 in FY25), Operational Adjusted EPS ($2.61), Adjusted Effective Tax Rate (17.4%), GAAP % to Sales ratios, and Full-Year 2026 Management Guidance ($101.2B reported sales / $11.10 adjusted EPS midpoint).
  • Groups 7–11 cover: (7) Balance Sheet Accrued Rebates, Returns & Promotions (GTN) Liability ($18,864M at Q3 2026), Major Wholesaler Revenue Concentration (Cencora 31.3%, McKesson 21.8%, Cardinal Health 12.6% in FY25), Advertising ($1,800M in FY25), Shipping & Handling (% of sales), and Restructuring; (8) Inventories by Stage ($13,517M net at Q3 2026: Raw Materials $1,943M, WIP $3,581M, Finished Goods $7,993M), PP&E by Category ($22,226M net at Q3 2026), Geographic PP&E across U.S., Europe, APAC/Africa & Western Hemisphere, Intangible Assets ($35,882M net at Q3 2026 with 5-year amortization schedule), and Operating Leases; (9) Debt & 5-Year Maturity Schedule ($39,719M total long-term debt at Q3 2026), Dividends ($3,275M / $1.35 per share in Q3 2026), Share Repurchases, Stock-Based Compensation, Deferred Tax Assets/Liabilities by Attribute, and Unrecognized Tax Benefits ($3,904M at FY25); (10) Global Workforce (140,800 employees / 138,200 FTEs in 10-K; 139,769 in HRIS across 4 regions), L&D Spend ($128M) & Training Hours (33.8 hrs/employee), CEO Pay Ratio (360:1 / $91,000 median employee in FY25), Form 11-K J&J Savings Plan ($26.89B net assets / $51.46B Master Trust in FY25), and Defined Benefit Pension ($29,572M PBO / $35,914M plan assets / +$6,342M funded status at FY25) & Postretirement Plans; and (11) Assured ESG & Sustainability Metrics from the 2025 Health for Humanity Report & Form SD (Community Giving $5,543M, 200M VERMOX doses, $16.2B Global Tax Contribution, 407 regulatory / 29 FDA inspections, 0.25 TRIR, Scope 1/2/3 GHG emissions, 100% renewable electricity, Water, Waste, 39,825 suppliers / $32.3B spend, and 218 in-scope 3TG suppliers / 340 verified SORs).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-10-25.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Consolidated Revenue, Geographic Disaggregation & Constant-Currency Growth Drivers

Innovative Medicine — Oncology & Immunology Therapeutic Areas & Key Drugs

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Johnson & Johnson

See a number that looks wrong?